Compare Cenovus Energy Inc (CVE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Gilead Sciences, Inc. — how do they compare? Cenovus Energy Inc trades at $31.38 (market cap $56.66B), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 3.2× Cenovus Energy Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Gilead Sciences, Inc. for 111 Days on average.
| CVE | GILD | |
|---|---|---|
Market Cap | $56.66B | $182.09B |
Volume | 7,667,753 | 4,960,247 |
Sector | Energy | Health |
52-Week High | $33.92 | $155.80 |
52-Week Low | $15.85 | $116.74 |
Typical Hold Time | 46 Days | 111 Days |
Enterprise Value | $62.61B | $205.15B |
Dividend Yield | 2.03% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 12.14, EV/EBITDA of 6.03, and robust profitability metrics including 20.96% ROE. Recent analyst coverage shows 40.74% buy ratings, while technical indicators point to support near $30 with resistance at $31-32 levels. Cash flow trends indicate operational strength with $8.23B from operations in 2025.
CVE presents a mixed outlook with attractive valuation metrics and strong profitability offset by bearish technical signals. The company's projected 2026 revenue growth to $58B and net income of $6.7B suggests upside potential, though energy sector volatility and recent price weakness near key support levels warrant caution. Analyst consensus leans positive with limited sell-side coverage.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
